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Summary
Objective: Osteoarthritis (OA) biomarkers are needed by researchers and clinicians to assist in disease diagnosis and assessment of disease
severity, risk of onset, and progression. As effective agents for OA are developed and tested in clinical studies, biomarkers that reliably mirror
or predict the progression or amelioration of OA will also be needed.
Methods: The NIH-funded OA Biomarkers Network is a multidisciplinary group interested in the development and validation of OA biomarkers.
This review summarizes our efforts to characterize and classify OA biomarkers.
Results: We propose the ‘‘BIPED’’ biomarker classiﬁcation (which stands for Burden of Disease, Investigative, Prognostic, Efﬁcacy of Inter-
vention and Diagnostic), and offer suggestions on optimal study design and analytic methods for use in OA investigations.
Conclusion: The BIPED classiﬁcation provides speciﬁc biomarker deﬁnitions with the goal of improving our ability to develop and analyze OA
biomarkers, and to communicate these advances within a common framework.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is one of the leading causes of chronic
disability. Recent estimates suggest that symptomatic
knee OA occurs in 13% of persons age 60 and over1, and
the prevalence is expected to increase further as the popu-
lation ages. There are a multitude of ways in which out-
comes in OA may be measured, including patient-relevant
measures (measures of pain and function), structural
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Received 20 March 2006; revision accepted 4 April 2006.72measures (such as plain radiographs and magnetic reso-
nance imaging), and biomarkers in the form of molecules
or molecular fragments that are released as a result of joint
tissue metabolism. Although a full understanding of OA re-
quires consideration of a range of biopsychosocial factors2,
our traditional method of deﬁning clinical OA has relied
upon plain radiography3.
Radiographic measures have been the traditional out-
comes in studies involving diagnosis and progression of
OA. Radiographic measures, however, are less than
adequate for diagnosing and assessing the actual progress
of this disease for several reasons. First, radiographs indi-
cate changes in bone, and only indirectly measure alter-
ations in cartilage. Second, the measurement of articular
cartilage change, namely joint space narrowing, is itself
confounded by meniscal cartilage lesions and meniscal
extrusion4. Third, bone marrow perturbations and synovial
abnormalities may go undetected. Radiographic features3
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tion has occurred both in the hard and soft tissues within
and around the joint and the change may occur relatively
slowly. Finally, radiographic features are usually poorly cor-
related with joint function. The interest in developing remit-
tive therapy has stimulated the search and development for
more sensitive indicators of OA for use in conjunction with,
or possibly as a substitute for, the traditional radiographic out-
comes.Preliminary studies suggest that both biomarkers and
magnetic resonance imaging (MRI) measurements are sen-
sitive to change. Biomarkers are deﬁned as objective indica-
tors of normal biologic processes, pathogenic processes, or
pharmacologic responses to therapeutic interventions5, and
have the potential to decrease the length and cost of trials
and enrich our understanding of the pathogenesis of OA.
Methods
The Osteoarthritis Biomarkers Network is a consortium of
ﬁve sites, funded by the National Institutes of Health/National
Institute of Arthritis, Musculoskeletal, and Skin Disease (NIH/
NIAMS) to develop and characterize new biomarkers and re-
ﬁne existing OA biomarkers. This consortium has adopted
a mandate to draft a classiﬁcation scheme for biomarkers
that could be employed in clinical trials and other studies of
OA. This classiﬁcation scheme is intended to capture infor-
mation in the early stages of biomarker development and
to facilitate the design of future validation studies with radio-
graphic or patient-centered outcomes. Such an approach
would be helpful in the appropriate allocation of potentially
scarce sample resources. Another advantage to awell-devel-
oped classiﬁcation scheme is the application of a common
biomarker vocabulary among investigators, their laboratories,
and potentially, across ﬁelds. A useful classiﬁcation scheme
would facilitate research (both independent and collabora-
tive), decrease redundancy, and expedite validation of po-
tential biomarkers.
Although biomarkers are classically thought of as biochem-
ical substances, it is also possible to consider RNA, DNA,
their fragments, or a combination or multiplicity of these, as
biomarkers. Although imaging techniques may themselves
be considered biomarkers for the pathologic joint abnormali-
ties that deﬁne OA, this paper addresses only protein and nu-
cleic acid based biomarkers. Similarly, traditional clinical risk
factors (such as bodymass index and gender)may be consid-
ered biomarkers by some, but clinical risk factors will not
be considered biomarkers for purposes of this classiﬁcation
schemeas they typically assess factors that increase the likeli-
hood of disease change but do not themselves reﬂect the
disease process.
The process of validation of any biomarker depends upon
the availability of a gold standard method for deﬁning
disease. The approach to biomarker development and
validation, typically a stepwise progression of studies that ul-
timately demonstrate anassociationwith the clinical outcome
of interest, is beyond the scope of this paper. An outline of
such procedures for markers in rheumatoid arthritis is pro-
vided in a recent review6. For the purposes of elucidating
the categories proposed here, we provide examples based
upon imaging outcome criteria against which OA biomarkers
may be validated. It is valuable to appreciate, however, that
other clinically relevant outcomes, such as pain, joint inﬂam-
mation, and function, could provide alternatives to structural
modiﬁcation as endpoints against which biomarkers can be
validated. Theprocess of biomarker validation should also in-
clude more patient-centered outcomes to complement mea-
sures of structure. However, until our currently limitedunderstanding of the biopsychosocial determinants of pain
and disability improves, the use of these clinical outcomes
will prove difﬁcult7.
Uniformguidelines for the technical speciﬁcationsof in vitro
diagnostic immunoassays already exist8. These published
guidelines encompass clinical performance of the assay, in-
cluding precision and variability (which must be met), but
not clinical utility, and are not discussed further here.
The proposed biomarker classiﬁcation scheme includes
ﬁve categories: diagnostic, burden of disease, prognostic, ef-
ﬁcacy of intervention, and investigative. These classiﬁcation
categories are developed to assist OA researchers with on-
going biomarker work, and in most instances, will be
achieved in a progressive validation strategy (Fig. 1). Thus,
a biomarker may fall into more than one category. Efforts
were made to maintain a clinical functionality to the classiﬁ-
cation scheme while minimizing redundancies.
Results
Based upon the considerations noted above, we propose
the following classiﬁcation of OA biomarkers.
DIAGNOSTIC MARKER
Diagnostic markers are deﬁned by the ability to classify
individuals as either diseased or non-diseased. New diag-
nostic tests should be evaluated by comparison against
an established gold standard in an appropriate spectrum
of subjects. For OA, an accepted ‘‘gold standard’’ diagnostic
test is the radiograph, and typically a KellgreneLawrence
(K-L) grade 2 is required for a diagnosis of OA9.
Studies of Diagnostic markers for OA must include
individuals with and without OA, and need to include a spec-
trum of subjects tested in terms of age, sex, disease sever-
ity, and speciﬁc eligibility criteria. Initially, the test should be
veriﬁed on a population from a cross-sectional dataset that







Fig. 1. Hypothetical development of OA biomarkers.
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with OA, such as rheumatoid arthritis. Caseecontrol de-
signs, where subjects with and without documented OA
are studied, are also suitable for the evaluation of Diagnos-
tic markers.
Diagnostic tests are seldom 100% accurate (false posi-
tives and false negatives will occur). A test is valid if it de-
tects most people with the target disorder (high sensitivity)
and excludes most people without the disorder (high spec-
iﬁcity), and if a positive test usually indicates that the disor-
der is present (high positive predictive value). In addition to
sensitivity and speciﬁcity, which are independent of disease
prevalence but are not useful to determine the probability
that a positive or negative test indicate those with or without
OA, other parameters are often used to assess the useful-
ness of a Diagnostic marker. The positive likelihood ratio
(LR) indicates how much more likely a positive test is to
be found in someone with, as opposed to without, the disor-
der10. Another useful diagnostic test parameter derived
from receiver operator curve (ROC) analyses is the area un-
der the curve (AUC), which quantiﬁes the overall ability of
a diagnostic test to classify diseased and non-diseased in-
dividuals correctly11. For example, Jung et al.12 recently
found that among 88 subjects with hip or knee OA and 48
age matched healthy controls, the mean level of urinary
CTXII was 527 ng/mmol for OA subjects and 190 ng/mmol
for the controls. The AUC for CTX-II was 0.92 (95% conﬁ-
dence interval [CI]: 0.87, 0.99) for hip OA and 0.82 (95%
CI: 0.73, 0.92) for knee OA. Although risk and odds ratios
(OR) are often reported in studies of Diagnostic markers,
unless extremely large, they provide little information about
the clinical utility of a Diagnostic marker13.
BURDEN OF DISEASE MARKER
Burden of diseasemarkers assess the severity or extent of
disease, typically at a single point in time, among individuals
with OA. This can be thought of as severity within a particular
joint, and/or severity in terms of number of joints involved.
The establishment of such a marker classiﬁcation is often
based on cross-sectional data of individuals with OA from co-
horts from the community or baseline assessments of sub-
jects enrolled in a clinical trial. This terminology is not to be
confused with the characterization of the economic and so-
cial impact of the disease often also referred to as ‘‘burden.’’
Studies of Burden of disease markers require comparison
with one or more gold standard methods of determining dis-
ease severity, such as radiographic criteria. The parameters
used to assess Burden of disease markers are similar to
those described for Diagnostic markers: sensitivity, speciﬁc-
ity, LRs, and AUC estimates derived from ROC analyses.
For example, studies of Burden of disease markers might
use AUC or LRs to describe how a test differentiates severity
of disease (e.g., delineating persons with K-L grade 2 radio-
graphic OA from those with K-L grade 3; or alternatively dif-
ferentiating persons with two joints involved from those with
three joints involved using a threshold criterion such as K-L
grade 2 to deﬁne disease).
Examples of Burden of disease marker exist in the OA
biomarker literature. These include serum cartilage oligo-
meric matrix protein (COMP)14, serum hyaluronan15, and
urinary CTXII16, to name a few.
PROGNOSTIC MARKER
The key feature of a Prognostic marker is the ability to
predict the future onset of OA among those without OA atbaseline or the progression of OA among those with exist-
ing disease. The optimal validation or application of a Prog-
nostic marker generally excludes individuals treated with
disease-modifying agents, but population-based samples
may include a small number of such individuals.
The evaluation of Prognostic markers requires longitudinal
studies (prospective or retrospective) showing an associa-
tion of the marker at baseline with the risk of development
of new OA (for example, new K-L grade> 1) or progression
(for example, at least one level increase in K-L grade). It is
valuable to recognize that some of today’s examples of
incident OAmay in fact later prove to be cases of progressive
OA as we become more sophisticated in our methods of
early OA detection. As measurements of biochemical
substances, molecules or fragments of protein, RNA or
DNA, and genotypes are potential Prognostic markers,
they may be analyzed as continuous, dichotomous, or cate-
gorical variables. Relevant outcomes in Prognostic marker
studies will usually be dichotomous (onset or progression:
yes vs no), but both categorical and continuous outcomes
from imaging assessments are acceptable, such as degree
of joint space narrowing or change in cartilage volume by
MRI.
The analytic approach to a Prognostic marker differs from
either Diagnostic or Burden of disease markers, as the
intent is to predict future conditions and not classify individ-
uals by disease or severity. Thus, for dichotomous or cate-
gorical outcomes, such as worsening K-L score, the
preferred methods of analyses are relative risk (RR) or
odds ratio (OR) given the presence or absence of the
marker. For Prognostic markers that are continuous, the
RR or OR per SD increase or decrease in the marker,
and/or the AUC estimated from ROC are accepted analytic
approaches. Genetic biomarkers are possible in this cate-
gory if they predict, for instance, a better or worse progno-
sis. For example, certain HLA-DRB1 gene polymorphisms
predict a more aggressive clinical course of rheumatoid ar-
thritis17. Currently, a comparable genetic Prognostic marker
for OA has not been described. As an example of a variant
Prognostic marker, Vilim et al.18 found that among individ-
uals with symptomatic knee OA, those with elevated levels
of serum COMP at baseline were more likely to show knee
OA progression deﬁned as an increase in one K-L grade or
joint space narrowing over 3 years.
Prognostic markers may also encompass some assess-
ment of disease activity. Our deliberations on the subject
of biomarker classiﬁcation revealed nuances of meaning
associated with markers that reﬂect disease activity. The
term ‘‘disease activity marker’’ is most often used to denote
a biomarker demonstrating meaningful variation in concert
with the varying phases of the disease, ranging from pe-
riods of structural or symptomatic progression to periods
of disease quiescence, and is therefore best considered
as Prognostic markers.
Two recent biomarker studies provide illustrative exam-
ples of Prognostic markers that appear to assess ‘‘disease
activity.’’ In the ﬁrst, Sharif et al.19 showed that mean serum
COMP levels (measured every 6 months in a cohort with
knee OA), were higher during periods of radiographic pro-
gression and that on average, a 1-unit increase in serum
COMP levels increased the probability of radiographic pro-
gression by 15%. In the second example, Garnero et al.20
recently found that the prevalence of bone marrow abn-
ormalities on MRI varied in 30% of the patients over a
3-month interval among individuals with painful knee OA.
Those with elevated levels of urinary CTX-II were more
likely to develop worsening bone marrow abnormalities on
726 D. C. Bauer et al.: Osteoarthritis biomarker reviewserial MRI measurements over this 3-month interval. In
these two examples, the phasic nature of the disease re-
ﬂected meaningful variation of the marker, and marker
levels were predictive of OA progression over intervals as
short as 3 months (urinary CTXII) and as long as several
years (COMP). A ‘‘disease activity marker’’ might also indi-
cate severity of disease within a joint or total extent of dis-
ease within a person. In this case, the marker is more
appropriately designated a Burden of disease marker as de-
scribed earlier.
EFFICACY OF INTERVENTION MARKER
An Efﬁcacy of intervention biomarker chieﬂy provides in-
formation about the efﬁcacy of treatment among those with
OA or those at high risk of developing OA. Efﬁcacy of inter-
vention markers may be measured prior to therapy to pre-
dict treatment efﬁcacy, or may be measured more than
once to assess short-term changes that occur as a result
of pharmacologic or other interventions. Candidate efﬁcacy
of intervention markers must be tested in a clinical trial with
appropriate OA outcomes, such as symptoms and/or func-
tion, or progression on imaging studies. Pre-treatment Efﬁ-
cacy of intervention markers may be variant or invariant, but
only variant markers may be used as serial determinants for
monitoring treatment efﬁcacy.
Serial assessments of Efﬁcacy of intervention markers
typically focus on the intervention group in a randomized
controlled trial. Most Efﬁcacy of intervention biomarkers
will be continuous. For studies of Efﬁcacy of intervention
markers with dichotomous outcomes, such as progression
vs no progression on imaging studies, logistic or hazard
models reporting the relative hazard or OR per unit or stan-
dard deviation of change in biomarker, or AUC from ROC
analyses are appropriate. For continuous outcomes, regres-
sion models relating change in biomarker (per unit or SD) to
change in the outcome variable are suggested.
To qualify for the Efﬁcacy of intervention category,
a marker must demonstrate a statistically signiﬁcant rela-
tionship between treatment-related changes in a biomarker
and the relevant clinical or radiographic OA outcomes. Ad-
ditional analyses, such as the proportion of treatment effect
explained21, may be estimated by comparing the treatmenteffect with and without the change in biomarker in the statis-
tical model.
A hypothetical example of an Efﬁcacy of intervention
marker is the case where concentrations of a biomarker
of cartilage degradation, measured serially, are associated
with an improved or beneﬁcial clinical or radiographic out-
come (dichotomous or continuous) among subjects who re-
ceive an effective OA intervention.
INVESTIGATIVE MARKER
An Investigative marker is one for which there is insufﬁ-
cient information to allow inclusion into one of the existing
categories. It can be represented by a genotype or an assay
of a molecule or fragment released into the synovial ﬂuid or
systemic circulation, where its relationship to various normal
and abnormal parameters of cartilage extracellular matrix
turnover has not yet been established in human subjects.
The purpose of creating this category in the classiﬁcation
scheme is to facilitate and encourage codiﬁcation of potential
OA biomarkers, and thereby engender further research de-
velopment aimed at establishing a role for the biomarker in
one or more of the other categories in the scheme.
Discussion
We propose a new classiﬁcation scheme for OA bio-
markers, which can be represented by the acronym BIPED
to connote the ﬁve categories of markers:Burden of disease,
Investigative, Prognostic, Efﬁcacy of intervention, and Diag-
nostic. As outlined above and in Table I, we have summa-
rized the deﬁnitions, characterized the subjects and typical
study design, and suggested preferred analytic approaches
for each marker category. For each biomarker, classiﬁcation
can be further deﬁned as variant (proteomic, RNA), or invari-
ant/less variant (DNA).Moreover, for each biomarker of inter-
est, one would want to know as much as possible about the
tissue(s) of origin, and biological processes reﬂected by the
biomarker, as well as a clear understanding of the nature of
the association of the biomarker with OA. The examples pre-
sented here readily demonstrate that a biomarker may ﬁt si-
multaneously into more than one category based upon the
weight of evidence at hand.Table I
Summary of ‘‘BIPED’’ biomarker classification for OA
Burden of disease Investigative Prognosis Efﬁcacy of intervention Diagnostic
Deﬁnition Biomarker associated















Variant only Variant or invariant Variant or invariant Variant or invariant Variant or invariant




NA Longitudinal Controlled trial Cross-sectional
or caseecontrol
Outcomes Extent or severity
of OA
NA New or worsening OA New or ameliorated OA OA vs no OA
Analysis Sensitivity, speciﬁcity,
LR, AUC from ROC
NA Risk or odds ratio
with 95% CI
Risk or odds ratio








extent or severity of OA
NA Signiﬁcant association
between marker and








727Osteoarthritis and Cartilage Vol. 14, No. 8The ultimate marker for clinical research purposes, a sur-
rogate endpoint, substitutes for a clinical outcome of how
a patient feels, functions, or survives5. This deﬁnition cuts
across all the classiﬁcation schemes and may apply to
any marker and is dependent on the proper validation study
to establish this relationship. However, markers that change
with a disease state (albeit Burden of disease markers or
Prognostic markers indicative of disease activity among un-
treated subjects, or serial Efﬁcacy of intervention markers
among treated subjects) are more readily accepted as sur-
rogate endpoints when they have proven dynamic modula-
tion with disease state. Surrogate markers have particular
value when resource constraints limit the extent to which
more costly outcomes can be conducted. Nevertheless,
as illustrated by this classiﬁcation scheme, markers in any
of the categories can provide useful information for clinical
and research applications. It is hoped that the development
of this classiﬁcation scheme will help to provide a common
language and structure with which to communicate knowl-
edge and advances related to OA biomarkers for both clin-
ical and research applications.
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